CD274 and neoplasm: The Phase III IMpower010 trial (24) demonstrated that atezolizumab significantly improved DFS compared with best supportive care in patients with stage II–IIIA NSCLC whose tumor cells expressed PD-L1 at a level of 1% or greater (TC ≥1%) following resection and chemotherapy (HR, 0.66, P = 0.0039) (17).